An ongoing dialogue on HIV/AIDS, infectious diseases,
March 20th, 2009
Hair Today, Gone Tomorrow …
Since providers — especially doctors — are notoriously poor at predicting medication adherence, here’s some good news: In a paper from the Women’s Interagency Health Study, protease inhibitor levels in hair samples were the strongest independent predictor of virologic success — better than self-reported adherence, age, race, baseline viral load and CD4 cell count, and prior experience with protease inhibitors.
That’s not all: Dr. Monica Gandhi (the lead investigator) describes the technique:
“We collect a small sample of hair from the back of their head and by small I mean 10 to 15 strands. So we collect after about a month of therapy a small thatch of hair from the back of your head and then grind it up and measure the anti-retroviral in that hair. And that gives us an idea after you start a new regimen whether you have enough in your system,” she says.
And in case you were wondering (were you?):
“One thing that people ask is can we use pubic hair for these measurements. And we don’t think that those are going to be useful because hair in those areas grow to a certain length and then they stop, which is great for anyone who has this hair. But you really want to measure hair that’s sort of growing continuously and that’s really scalp hair,” she says.
Every so often I’m reminded that HIV medicine isn’t like other fields — and that paragraph says it all!
(Hat tip to R Plank for the reference.)
Categories: HIV, Infectious Diseases, Patient Care
Tags: ART, baseline, CD4, Dr. Monica Gandhi, hair samples, HIV, HIV medicine, monica gandhi, predictor, protease inhibitor, protease inhibitors, R Plank, scalp hair, viral load
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
Sorry. No data so far.
-
From the Blog — Most Recent Articles
- Farewell to This Blog — and Hello to NEJM Voices March 2, 2026
- Some Ruminations on CROI — Still the Best HIV Meeting February 26, 2026
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing February 17, 2026
- Sometimes You Just Need to Get Input from a Real Human Being February 12, 2026
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
FROM NEJM — Recent Infectious Disease Articles- The End of the War on Biomedical Science? September 19, 2026The turmoil of the past 20 months has inflicted lasting damage on American science and public health. But history and recent events suggest that the attacks will subside.
- Cerebral Schistosomiasis September 19, 2026A rice farmer presented to the ED after a 1-minute episode of arm and leg shaking on the right side. MRI showed linear enhancement associated with a cluster of enhancing nodules and surrounding edema in the left frontal lobe.
- Human Adenovirus B3–Induced Immune Thrombocytopenia and Thrombosis September 17, 2026Virus-induced immune thrombocytopenia and thrombosis after HAdV-B3 infection supports a shared platelet factor 4–targeted immune mechanism linking natural adenovirus infection and adenoviral vector–associated disease.
- Honoring the Legacy of the HIV Epidemic September 17, 2026Progress against the U.S. HIV epidemic is stalling, owing in part to government attacks and fear. But clinicians, patients, and activists can learn from the epidemic’s early heroes and find ways to advance.
- Short or Long Antibiotic Regimens in Orthopedics September 16, 2026In a randomized trial involving adults who received local antibiotics during surgery for orthopedic infection, a short duration of systemic antibiotics was noninferior to a long duration regarding treatment failure at 12 months.
- The End of the War on Biomedical Science? September 19, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
